Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Dec 13;12(12):1445.
doi: 10.3390/pathogens12121445.

Plasmodium vivax Malaria and G6PD Testing

Affiliations
Editorial

Plasmodium vivax Malaria and G6PD Testing

Benedikt Ley et al. Pathogens. .

Abstract

Early malaria investigators were certainly correct in classifying the species falciparum and the species vivax as belonging to the same genus, Plasmodium [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Genetics and pharmacogenetics of G6PD deficiency: a triangular relationship. One vertex of the virtual triangle is G6PD deficiency due to a mutation in the human G6PD gene located on the tip of the long arm of the X chromosome (Xq28). Like any other gene, G6PD is susceptible to spontaneous mutations, and some of these entail G6PD deficiency. Another vertex is the malaria parasite; when it infects heterozygotes, in whom G6PD normal red cells (pink) and G6PD deficient red cells (grey) co-exist, this mosaicism is key to protection [28], at least in the case of P. falciparum. As a result, genetically determined G6PD deficiency tends to become prevalent in malaria-endemic areas. The third vertex are 8-aminoquinolines, potent hypnozoitocides that, by producing reactive oxygen species (ROS), kill P. vivax hypnozoites [35]; unfortunately, ROS also cause oxidative injury to G6PD deficient red cells, thus causing acute haemolytic anaemia in G6PD-deficient persons. RBC = red blood cell.

References

    1. Baird J.K. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin. Microbiol. Rev. 2013;26:36–57. doi: 10.1128/CMR.00074-12. - DOI - PMC - PubMed
    1. Ashley E.A., Recht J., White N.J. Primaquine: The risks and the benefits. Malar. J. 2014;13:418. doi: 10.1186/1475-2875-13-418. - DOI - PMC - PubMed
    1. Llanos-Cuentas A., Lacerda M.V.G., Hien T.T., Velez I.D., Namaik-Larp C., Chu C.S., Villegas M.F., Val F., Monteiro W.M., Brito M.A.M., et al. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. N. Engl. J. Med. 2019;380:229–241. doi: 10.1056/NEJMoa1802537. - DOI - PMC - PubMed
    1. Fletcher K.A., Evans D.A., Gilles H.M., Greaves J., Bunnag D., Harinasuta T. Studies on the pharmacokinetics of primaquine. Bull. World Health Organ. 1981;59:407–412. - PMC - PubMed
    1. Charles B.G., Miller A.K., Nasveld P.E., Reid M.G., Harris I.E., Edstein M.D. Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects. Antimicrob. Agents Chemother. 2007;51:2709–2715. doi: 10.1128/AAC.01183-06. - DOI - PMC - PubMed

Publication types

LinkOut - more resources